The independent source for health policy research, polling, and news.
401-420 of 480 results
The complete findings of a recent study show the FDA-approved drug Vascepa reduced the likelihood of cardiovascular death, stroke and other heart conditions in some patients. But science didn’t find the same promise for over-the-counter fish oil supplements when tested in healthy people.
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
Critics worry the marketing of Vascepa, a purified fish oil product, could prove a fish story.
Dieters and gym rats, beware. Some dietary supplements promising weight loss or more muscle may contain active ingredients not listed on the label that fly under the radar of the Food and Drug Administration. The California Department of Public Health analyzed public data maintained by the FDA to suss out trends among tainted products, raising red flags.
In this episode of KHN’s “What the Health?” Mary Agnes Carey of Kaiser Health News, Rebecca Adams of CQ Roll Call, Anna Edney of Bloomberg News and Julie Appleby of Kaiser Health News discuss the Trump administration’s announcement that average premium prices are falling on the Obamacare marketplaces, the effort by Senate Democrats to reverse rules on short-term health insurance and the focus on protections for people with preexisting conditions in the run-up to midterm elections.
Just weeks before midterm elections, a move by federal health officials spotlights a contentious issue: the use of human fetal tissue in research. Here’s what you need to know to understand the debate.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Rebecca Adams of CQ Roll Call, Margot Sanger-Katz of The New York Times and Kimberly Leonard of the Washington Examiner discuss final action on bills in Congress to address the opioid epidemic and fund federal health agencies. They also look at new efforts by the Food and Drug Administration to crack down on teen nicotine use.
Pharmaceutical companies like Purdue Pharma, maker of OxyContin, often win patents for incremental changes with debatable value. Now there’s a twist involving an opioid treatment.
The protection is a win for people who get their needed, legitimate drugs from overseas.
Medicaid drug spending doubled in five years in Massachusetts. The state wanted to exclude expensive drugs that weren't proven to work better than existing alternatives from its Medicaid plan, but the federal government blocked the effort.
An annual government survey of drug use and health shows a dramatic drop in the number of people who tried heroin but an uptick in pot use.
In this episode of KHN’s “What the Health?” Sarah Jane Tribble of Kaiser Health News, Stephanie Armour of The Wall Street Journal, Kimberly Leonard of the Washington Examiner and Rebecca Adams of CQ Roll Call talk about the Food and Drug Administration’s latest actions to address teenagers’ use of e-cigarettes, Arkansas’ Medicaid work requirements and news about the uninsured from the latest federal Census report.
The Golden State, with the rare support of the Trump administration, is seeking to circumvent a court order that would require cancer warnings in every establishment that sells a hot cup of Joe.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Alice Ollstein of Talking Points Memo, Margot Sanger-Katz of The New York Times and Joanne Kenen of Politico discuss Senate action on health funding and opioid legislation, the state of the individual insurance market and consternation over expiration dates on EpiPens, the self-injected allergy remedy. Also, could an otter with asthma signal a potential public health crisis?
Critics worry about the message federal officials are sending by approving a new birth control option, which uses a mobile phone app for women to track their body temperature and menstrual cycle to avoid pregnancy. But the more choices the better, some reproductive health experts say.
Instead of waiting for congressional action, federal regulators are looking at a series of actions to spur competition and drive down the cost of medicines.
Inspector general identifies possible problems in nearly 23 percent of pharmacies that bill Medicare for blended creams, gels and lotions.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Anna Edney of Bloomberg News, Alice Ollstein of Talking Points Memo and Kimberly Leonard of the Washington Examiner talk about the new push on health legislation by Republicans in the House, as well as developments on Medicaid work requirements, drug prices and the fate of children separated from their parents at the U.S.-Mexican border. Plus, for extra credit, the panelists offer their favorite health stories of the week.
KHN’s newsletter editor, Brianna Labuskes, wades through hundreds of health articles from the week so you don’t have to.
Dr. Mark McClellan joined Johnson & Johnson’s board of directors after leaving the FDA, but the connection often isn’t mentioned in research papers or public events.
© 2026 KFF